Lioresal
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.87 | $52.00 (0%) | 🛒 Add to cart |
| 90 | $0.80 | $78.00 $72.00 (8%) | 🛒 Add to cart |
| 120 | $0.77 | $104.00 $92.00 (12%) | 🛒 Add to cart |
| 180 | $0.72 | $156.00 $130.00 (17%) | 🛒 Add to cart |
| 270 | $0.70 | $234.00 $190.00 (19%) | 🛒 Add to cart |
| 360 | $0.69
Best per pill | $312.00 $249.00 (20%) | 🛒 Add to cart |
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.53 | $76.00 (0%) | 🛒 Add to cart |
| 60 | $2.12 | $152.00 $127.00 (16%) | 🛒 Add to cart |
| 90 | $1.97 | $228.00 $177.00 (22%) | 🛒 Add to cart |
| 120 | $1.89 | $304.00 $227.00 (25%) | 🛒 Add to cart |
| 180 | $1.82 | $456.00 $328.00 (28%) | 🛒 Add to cart |
| 270 | $1.77
Best per pill | $684.00 $478.00 (30%) | 🛒 Add to cart |
Synonyms | |||
More info:
Abilify: Advanced Antipsychotic for Symptom Control and Stability
Abilify (aripiprazole) is an atypical antipsychotic medication engineered to provide a sophisticated mechanism of action for managing complex psychiatric conditions. It functions as a partial agonist, offering a unique modulatory effect on dopamine and serotonin receptors, which contributes to its efficacy and generally favorable tolerability profile. This medication is a cornerstone in the long-term management of schizophrenia, bipolar disorder, and as an adjunct in major depressive disorder, providing patients with a path toward sustained symptom control and improved functional outcomes.
Amitriptyline: Effective Relief for Chronic Pain and Depression
Amitriptyline is a tricyclic antidepressant (TCA) with a well-established profile for managing major depressive disorder and a range of chronic pain conditions. Its dual-action mechanism modulates serotonin and norepinephrine reuptake, offering both mood stabilization and central pain modulation. It is particularly valued in clinical practice for its efficacy in neuropathic pain, migraine prophylaxis, and as a second-line option for depression when SSRIs are ineffective or poorly tolerated. This product card provides a comprehensive, evidence-based overview for healthcare professionals.
Anafranil: Restoring Balance in Severe OCD Treatment
Anafranil (clomipramine hydrochloride) is a tricyclic antidepressant (TCA) with potent serotonin reuptake inhibition properties, specifically approved for the treatment of obsessive-compulsive disorder (OCD). It represents a foundational pharmacological intervention for moderate to severe OCD cases where first-line treatments prove insufficient. Its efficacy is well-documented in clinical literature, offering a robust option for patients struggling with intrusive thoughts and compulsive behaviors. By modulating key neurotransmitter systems, it helps reduce the core symptoms that significantly impair daily functioning and quality of life.
Asendin: Targeted Relief for Endogenous Depression with Dual-Action Efficacy
Asendin (amoxapine) is a tetracyclic antidepressant (TeCA) medication indicated for the relief of symptoms of endogenous depression. It represents a distinct class of agent that combines potent norepinephrine reuptake inhibition with secondary dopamine receptor blockade, offering a unique neurochemical profile for cases where first-line selective serotonin reuptake inhibitors (SSRIs) prove inadequate or intolerable. Its mechanism provides a rapid onset of action for certain symptoms, particularly psychomotor retardation, often within the first week of treatment.
Bupropion SR: Effective Relief for Major Depressive Disorder
Bupropion SR (sustained-release) is a widely prescribed antidepressant belonging to the aminoketone class, distinct from SSRIs and SNRIs. It functions primarily as a norepinephrine–dopamine reuptake inhibitor (NDRI), offering a unique mechanism of action for managing major depressive disorder. This formulation provides steady plasma concentrations over 12 hours, supporting consistent therapeutic effect with twice-daily dosing. Clinicians often favor bupropion SR for its favorable side effect profile, particularly the low incidence of sexual dysfunction and weight gain associated with other antidepressants.
Bupropion: A Leading Antidepressant for Depression and Smoking Cessation
Bupropion is a widely prescribed antidepressant medication belonging to the class of norepinephrine-dopamine reuptake inhibitors (NDRIs). It is primarily indicated for the treatment of major depressive disorder (MDD) and to aid in smoking cessation. Unlike many other antidepressants, bupropion does not significantly affect serotonin levels, which contributes to its distinct side effect profile and makes it a favorable option for patients who cannot tolerate serotonergic agents. Its dual mechanism of action enhances norepinephrine and dopamine neurotransmission, which is associated with improvements in mood, energy, and motivation.
Celexa: Effective SSRI Treatment for Major Depressive Disorder
Celexa (citalopram hydrobromide) is a selective serotonin reuptake inhibitor (SSRI) prescription medication clinically proven to manage symptoms of major depressive disorder in adults. Developed through extensive pharmacological research, this antidepressant works by restoring serotonin balance in the brain, a neurotransmitter critically involved in mood regulation. With well-established efficacy and a generally favorable tolerability profile, Celexa represents a first-line treatment option for depression management. Healthcare providers frequently prescribe this medication due to its demonstrated effectiveness in improving mood, energy levels, and interest in daily activities.
Clozaril: A Breakthrough in Treatment-Resistant Schizophrenia Management
Clozaril (clozapine) represents a significant advancement in the pharmacological management of severe, treatment-resistant schizophrenia. As the first atypical antipsychotic approved by the FDA, it operates through a unique receptor profile distinct from conventional antipsychotics, offering a critical therapeutic option where other agents have failed. Its use is strictly regulated due to the risk of serious adverse effects, necessitating a rigorous monitoring protocol to ensure patient safety. This agent is reserved for cases that have not responded adequately to standard antipsychotic treatment, providing a pathway to stability for a complex patient population.
Cymbalta: Comprehensive Relief for Depression and Chronic Pain
Cymbalta (duloxetine) is a prescription medication classified as a serotonin-norepinephrine reuptake inhibitor (SNRI). It is FDA-approved for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. By modulating key neurotransmitters in the central nervous system, Cymbalta addresses both the emotional and physical dimensions of these conditions, offering a dual mechanism of action that distinguishes it from many conventional antidepressants. Its efficacy is supported by extensive clinical trials and long-term use in diverse patient populations.